Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22042169 | 0.80 | ALDH1A1 (0.44) | SNCAHDAC8 | |
| SCHEMBL928439 | 0.78 | SNCA (0.55) | SNCAKDRSMN1; SMN2CCNE1CDK2 | |
| SCHEMBL13142474 | 0.75 | SNCA (0.66) | SNCAKDRSMN1; SMN2CCNE1CDK2 | |
| SCHEMBL10013471 | 0.75 | SNCA (0.51) | SNCAHDAC8SMN1; SMN2CDK2 | |
| SCHEMBL14157145 | 0.75 | SNCA (0.66) | SNCASMN1; SMN2 | |
| SCHEMBL25382795 | 0.75 | SNCA (0.56) | SNCAHDAC8SMN1; SMN2 | |
| SCHEMBL22466129 | 0.75 | SNCA (0.56) | SNCAHDAC8SMN1; SMN2 | |
| SCHEMBL20641446 | 0.75 | SNCA (0.56) | SNCASMN1; SMN2CDK2 | |
| SCHEMBL5561901 | 0.75 | SNCA (0.51) | SNCAKDRSMN1; SMN2CCNE1CDK2 | |
| SCHEMBL6505980 | 0.73 | KDM4E (0.57) | SNCAKDRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111285850-B | Isoindoline compounds, preparation method thereof, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2022-04-22 | — | — | CN | disclosed |
| US-20220041578-A1 | ISOINDOLINE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION OF ISOINDOLINE COMPOUND | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2022-02-10 | — | — | US | disclosed |
| EP-3896062-A1 | ISOINDOLINE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION OF ISOINDOLINE COMPOUND | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2021-10-20 | — | — | EP | disclosed |
| WO-2020114482-A1 | ISOINDOLINE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION OF ISOINDOLINE COMPOUND | 中国科学院上海药物研究所 | 2020-06-11 | — | — | WO | disclosed |
| EP-2499132-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-02-15 | — | — | EP | disclosed |
| EP-2499132-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-02-15 | — | — | EP | disclosed |
| EP-2612861-B1 | FLUORINATED THIAZOLES FOR USE IN TREATING CANCER | UNIV BARCELONA (ES) | 2015-05-13 | — | — | EP | disclosed |
| EP-2612861-B1 | FLUORINATED THIAZOLES FOR USE IN TREATING CANCER | UNIV BARCELONA (ES) | 2015-05-13 | — | — | EP | disclosed |
| US-8680126-B2 | Fluorinated thiazoles for use in treating cancer | UNIVERSITAT DE BARCELONA (ES) | 2014-03-25 | — | — | US | disclosed |
| US-8680126-B2 | Fluorinated thiazoles for use in treating cancer | UNIVERSITAT DE BARCELONA (ES) | 2014-03-25 | — | — | US | disclosed |
| WO-2011060000-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
| US-7709829-B2 | Organic semiconductor material, organic transistor, field effect transistor, switching device and thiazole compound | KONICA MINOLTA HOLDINGS, INC. (JP) | 2010-05-04 | — | — | US | disclosed |
| US-7709829-B2 | Organic semiconductor material, organic transistor, field effect transistor, switching device and thiazole compound | KONICA MINOLTA HOLDINGS, INC. (JP) | 2010-05-04 | — | — | US | disclosed |
| US-20080283828-A1 | Organic semiconductor polymer having liquid crystal properties, organic active layer, organic thin film transistor, and electronic device including the same, and methods of fabricating the same | SAMSUNG ELECTRONICS CO., LTD. | 2008-11-20 | — | — | US | disclosed |
| US-20080283828-A1 | Organic semiconductor polymer having liquid crystal properties, organic active layer, organic thin film transistor, and electronic device including the same, and methods of fabricating the same | SAMSUNG ELECTRONICS CO., LTD. | 2008-11-20 | — | — | US | disclosed |
| US-20080283828-A1 | Organic semiconductor polymer having liquid crystal properties, organic active layer, organic thin film transistor, and electronic device including the same, and methods of fabricating the same | SAMSUNG ELECTRONICS CO., LTD. | 2008-11-20 | — | — | US | disclosed |
| EP-1993105-A1 | Organic semiconductor polymer having liquid crystal properties, organic active layer, organic thin film transistor, and electronic device including the same, and methods of fabricating the same | Samsung Electronics Co., Ltd. (KR) | 2008-11-19 | — | — | EP | disclosed |
| US-20080251784-A1 | Organic Semiconductor Material, Organic Transistor, Field Effect Transistor, Switching Device and Thiazole Compound | EDISON INNOVATIONS LLC | 2008-10-16 | — | — | US | disclosed |
| US-20080251784-A1 | Organic Semiconductor Material, Organic Transistor, Field Effect Transistor, Switching Device and Thiazole Compound | EDISON INNOVATIONS LLC | 2008-10-16 | — | — | US | disclosed |
| US-6054435-A | 6-O-substituted macrolides having antibacterial activity | ABBOTT LABORATORIES (US) | 2000-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041578-A1 | ISOINDOLINE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION OF ISOINDOLINE COMPOUND | CRBN, CUL4B, UBQLN1 | SNCA 3758/4885KDR 2496/4885HDAC8 2687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.